Moxclav and Augmentin are the same medication [1]. Both are brand names for a combination drug containing amoxicillin and clavulanate potassium [1][2]. This combination is a penicillin-type antibiotic used to treat various bacterial infections, including those of the lungs, ear, nose, throat, skin, and urinary tract [1].
Why are they called different names?
Different pharmaceutical companies may market the same generic drug under various brand names [3]. This practice allows companies to distinguish their product in the market and can sometimes be related to regional marketing or specific formulations [3]. For instance, Augmentin is a well-known brand name for amoxicillin/clavulanate, while Moxclav is another brand name for the identical combination [1].
How does amoxicillin and clavulanate potassium work?
Amoxicillin is a penicillin antibiotic that works by preventing bacteria from building their cell walls [1]. However, some bacteria produce enzymes called beta-lactamases, which can break down amoxicillin, rendering it ineffective [1]. Clavulanate potassium is a beta-lactamase inhibitor [1]. When combined with amoxicillin, clavulanate potassium protects amoxicillin from being destroyed by these enzymes, thereby extending its ability to kill bacteria [1].
What infections can this medication treat?
The combination of amoxicillin and clavulanate potassium is prescribed for a range of bacterial infections. These include respiratory tract infections like pneumonia and bronchitis, sinus infections (sinusitis), ear infections (otitis media), and skin infections such as cellulitis [1]. It is also used for urinary tract infections [1].
When does the patent for Augmentin expire?
Information regarding the patent expiration for specific brand-name drugs like Augmentin can be found through resources that track pharmaceutical patents [4]. Patent expiry dates are crucial for determining when generic versions of a drug can enter the market, potentially leading to lower prices [4]. DrugPatentWatch.com is a resource that provides such patent information [4].